Buspar
Result: $90 million settlement
Year: 2003
In re Buspirone Antitrust Litigation
In November 2003, Lieff Cabraser obtained a $90 million cash settlement for individual consumers, consumer organizations, and third party payers that purchased BuSpar, a drug prescribed to alleviate symptoms of anxiety.
Plaintiffs alleged that Bristol-Myers Squibb Co. (BMS), Danbury Pharmacal, Inc., Watson Pharmaceuticals, Inc. and Watson Pharma, Inc. entered into an unlawful agreement in restraint of trade under which BMS paid a potential generic manufacturer of BuSpar to drop its challenge to BMS’ patent and refrain from entering the market.
Lieff Cabraser served as Plaintiffs’ Co-Lead Counsel.
Civil Litigation News
Douglas Cuthbertson to Discuss “Consumer Data Privacy” at Upcoming NASCAT Annual Meeting
Lieff Cabraser partner Douglas Cuthbertson will be a featured speaker at the 2025 NASCAT annual meeting. Doug will be speaking on the
San Francisco Schools Receive Financial Boost From Settlement With JUUL
As reported by the S.F. Chronicle, the San Francisco Unified School District has been awarded a substantial $24.65
Final Approval Granted to Historic $235M Settlement with Altria in National JUUL Youth E-Cigarette Predatory Advertising, Addiction and Injury Litigation
On March 14, 2024, U.S. District Judge William Orrick of the Northern District of California issued an order granting final approval to a comprehensive
